Summary
Eli Lilly & Co. (LLY) filed an 8-K on December 22, 2005, detailing executive and director compensation for 2006 and announcing significant restructuring charges. The company's Compensation Committee approved compensation packages for its named executive officers, including base salary, target bonuses, stock options, and performance awards, with compensation levels varying based on executive roles. Additionally, non-employee directors will receive annual retainers and stock awards, with provisions for deferral plans. The most significant financial update in this filing concerns material impairments and exit activities. Lilly anticipates a pre-tax charge of $170 million to $190 million in the fourth quarter of 2005. This charge is primarily composed of non-cash asset write-downs for manufacturing and R&D equipment no longer deemed necessary, estimated at $155 million to $165 million pre-tax. The remaining portion of the charge relates to cash expenditures for contract terminations and employee-related costs, expected to be incurred over the next three years.
Key Highlights
- 1Approved 2006 compensation for named executive officers, including salaries, bonuses, stock options, and performance awards.
- 2Details 2006 compensation for non-employee directors, including cash retainers, meeting fees, and stock awards.
- 3Announced a pre-tax charge of $170 million to $190 million for the fourth quarter of 2005 related to restructuring and impairments.
- 4The majority of the charge ($155-$165 million pre-tax) is non-cash, stemming from write-downs of impaired manufacturing and R&D assets.
- 5Estimated cash expenditures for exit activities are $15-$25 million pre-tax, to be paid over the next three years.
- 6The impairment charges are intended to adjust the carrying value of assets to fair value due to no future use.
- 7The filing addresses executive and director compensation arrangements, signaling potential changes in incentive structures and board remuneration.